Voyager Therapeutics Inc
NASDAQ:VYGR
Net Margin
Voyager Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
188.5m USD |
-81%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
336.8B USD |
8%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
150.9B USD |
12%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
131B USD |
2%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126B USD |
-5%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
118.3B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
66.1B USD |
31%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
32.7B EUR |
38%
|
Voyager Therapeutics Inc
Glance View
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Voyager Therapeutics Inc's most recent financial statements, the company has Net Margin of -81.3%.
You don't have any saved screeners yet